Literature DB >> 12086975

The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents.

J-M Rigo1, G Hans, L Nguyen, V Rocher, S Belachew, B Malgrange, P Leprince, G Moonen, I Selak, A Matagne, H Klitgaard.   

Abstract

1. In this study in vitro and in vivo approaches were combined in order to investigate if the anti-epileptic mechanism(s) of action of levetiracetam (LEV; Keppra) may involve modulation of inhibitory neurotransmission. 2. GABA- and glycine-gated currents were studied in vitro using whole-cell patch-clamp techniques applied on cultured cerebellar granule, hippocampal and spinal neurons. Protection against clonic convulsions was assessed in vivo in sound-susceptible mice. The effect of LEV was compared with reference anti-epileptic drugs (AEDs): carbamazepine, phenytoin, valproate, clonazepam, phenobarbital and ethosuximide. 3. LEV contrasted the reference AEDs by an absence of any direct effect on glycine-gated currents. At high concentrations, beyond therapeutic relevance, it induced a small reduction in the peak amplitude and a prolongation of the decay phase of GABA-gated currents. A similar action on GABA-elicited currents was observed with the reference AEDs, except ethosuximide. 4. These minor direct effects contrasted with a potent ability of LEV (EC(50)=1 - 10 microM) to reverse the inhibitory effects of the negative allosteric modulators zinc and beta-carbolines on both GABA(A) and glycine receptor-mediated responses. 5. Clonazepam, phenobarbital and valproate showed a similar ability to reverse the inhibition of beta-carbolines on GABA-gated currents. Blockade of zinc inhibition of GABA responses was observed with clonazepam and ethosuximide. Phenytoin was the only AED together with LEV that inhibited the antagonism of zinc on glycine-gated currents and only clonazepam and phenobarbital inhibited the action of DMCM. 6. LEV (17 mg kg(-1)) produced a potent suppression of sound-induced clonic convulsions in mice. This protective effect was significantly abolished by co-administration of the beta-carboline FG 7142, from a dose of 5 mg kg(-1). In contrast, the benzodiazepine receptor antagonist flumazenil (up to 10 mg kg(-1)) was without any effect on the protection afforded by LEV. 7. The results of the present study suggest that a novel ability to oppose the action of negative modulators on the two main inhibitory ionotropic receptors may be of relevance for the anti-epileptic mechanism(s) of action of LEV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086975      PMCID: PMC1573396          DOI: 10.1038/sj.bjp.0704766

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

Review 1.  Glycine receptors: what gets in and why?

Authors:  P H Barry; P R Schofield; A J Moorhouse
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-11       Impact factor: 2.557

2.  Effects of valproate, vigabatrin and tiagabine on GABA uptake into human astrocytes cultured from foetal and adult brain tissue.

Authors:  C M Fraser; G J Sills; E Butler; G G Thompson; K Lindsay; R Duncan; A Howatson; M J Brodie
Journal:  Epileptic Disord       Date:  1999-09       Impact factor: 1.819

Review 3.  Mossy fiber zinc and temporal lobe epilepsy: pathological association with altered "epileptic" gamma-aminobutyric acid A receptors in dentate granule cells.

Authors:  D A Coulter
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

Review 4.  What is GABAergic inhibition? How is it modified in epilepsy?

Authors:  C Bernard; R Cossart; J C Hirsch; M Esclapez; Y Ben-Ari
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

5.  Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs.

Authors:  D G Margineanu; H Klitgaard
Journal:  Pharmacol Res       Date:  2000-10       Impact factor: 7.658

6.  Antiepileptic efficacy of topiramate: assessment in two in vitro seizure models.

Authors:  S S Jahromi; M R Pelletier; P J McDonald; H Khosravani; P L Carlen
Journal:  Brain Res       Date:  2000-07-28       Impact factor: 3.252

7.  Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex-hippocampal slices.

Authors:  C Brückner; U Heinemann
Journal:  Brain Res       Date:  2000-03-17       Impact factor: 3.252

8.  Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy.

Authors:  A J Gower; E Hirsch; A Boehrer; M Noyer; C Marescaux
Journal:  Epilepsy Res       Date:  1995-11       Impact factor: 3.045

Review 9.  From ion currents to genomic analysis: recent advances in GABAA receptor research.

Authors:  L E Rabow; S J Russek; D H Farb
Journal:  Synapse       Date:  1995-11       Impact factor: 2.562

10.  The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes.

Authors:  M Noyer; M Gillard; A Matagne; J P Hénichart; E Wülfert
Journal:  Eur J Pharmacol       Date:  1995-11-14       Impact factor: 4.432

View more
  62 in total

1.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin.

Authors:  Bjørnar Hassel; Erik Taubøll; Renee Shaw; Leif Gjerstad; Ray Dingledine
Journal:  Epilepsia       Date:  2010-09       Impact factor: 5.864

4.  Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus.

Authors:  Chun-Yao Lee; Chih-Chuan Chen; Horng-Huei Liou
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

5.  Levetiracetam-induced acute psychotic episode.

Authors:  Srinivas Dannaram; Dileep Borra; Madhuri Pulluri; Prachi Jindal; Ashish Sharma
Journal:  Innov Clin Neurosci       Date:  2012-10

6.  Glycine receptors support excitatory neurotransmitter release in developing mouse visual cortex.

Authors:  Portia A Kunz; Alain C Burette; Richard J Weinberg; Benjamin D Philpot
Journal:  J Physiol       Date:  2012-09-17       Impact factor: 5.182

7.  Levetiracetam inhibits Na+-dependent Cl-/HCO3- exchange of adult hippocampal CA3 neurons from guinea-pigs.

Authors:  Tobias Leniger; Jan Thöne; Udo Bonnet; Andreas Hufnagel; Dieter Bingmann; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

8.  Levetiracetam has no acute effects on brain gamma-aminobutyric acid levels.

Authors:  R Kuzniecky; J Pan; A Burns; O Devinsky; H Hetherington
Journal:  Epilepsy Behav       Date:  2008-02       Impact factor: 2.937

9.  Levetiracetam as an alternative therapy for Tourette syndrome.

Authors:  M A Martínez-Granero; A García-Pérez; F Montañes
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

10.  Modifications of antiepileptic drugs for improved tolerability and efficacy.

Authors:  Cecilie Johannessen Landmark; Svein I Johannessen
Journal:  Perspect Medicin Chem       Date:  2008-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.